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Abstract
Immunoinformatics is a discipline that applies methods of computer sci-
ence to study and model the immune system. A fundamental question ad-
dressed by immunoinformatics is how to understand the rules of antigen
presentation by MHC molecules to T cells, a process that is central to
adaptive immune responses to infections and cancer. In the modern era
of personalized medicine, the ability to model and predict which antigens
can be presented by MHC is key to manipulating the immune system and
designing strategies for therapeutic intervention. Since the MHC is both
polygenic and extremely polymorphic, each individual possesses a personal-
ized set of MHC molecules with different peptide-binding specificities, and
collectively they present a unique individualized peptide imprint of the
ongoing protein metabolism. Mapping all MHC allotypes is an enormous
undertaking that cannot be achieved without a strong bioinformatics com-
ponent. Computational tools for the prediction of peptide–MHC binding
have thus become essential in most pipelines for T cell epitope discovery and
an inescapable component of vaccine and cancer research.Here, we describe
the development of several such tools, from pioneering efforts to the cur-
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peptide binding of all MHCmolecules, even including those that have not yet been characterized
experimentally.
INTRODUCTION
Our survival depends on an immune system that can eradicate biological threats like infections
and cancer. Studying and modeling the immune system, in both health and disease, are central to
the development of clinical interventions to a wide array of diseases, from cancer to infections and
autoimmune disorders. As in many other fields in biology, the growing amount of immunological
data generated by increasingly high-throughput methods requires the development of efficient
computational methods. The emerging field of immunoinformatics sits at the intersection of im-
munology and computer science and aims to provide algorithms and analytical tools to aid the
interpretation of immunological data and processes (1).
The ability to recognize targets of foreign origin (nonself ) without attacking the tissues of the
host (self ) is a hallmark of the immune system and is primarily the function of T cells. T cells
recognize their targets in cell–cell interactions, which involve T cell receptors (TCRs) and, as
ligands, peptide–major histocompatibility complex (MHC) complexes (pMHCs) expressed by
antigen-presenting cells (APCs). In the thymus, highly diverse peptide-specific, MHC-restricted
TCR repertoires are generated by somatic gene rearrangements, each of which is expressed by a
rare T cell clone. Through positive and negative selection, the T cells are educated to recognize
self-MHC and tolerate any presented self-peptide. This creates a naïve T cell repertoire that is
self-MHC restricted and prepared to recognize foreign (nonself ) peptides encountered in the
periphery at later times (2). Should that happen, a specific primary adaptive immune response
occurs in which one or more naïve T cell clones of appropriate specificities are selected, activated,
and expanded. Eventually, such expanded T cell clones contract, leaving behind persistent pools
of specific memory T cells, which upon reexposure to the pathogen are rapidly recruitable and
potentially afford lifelong protection.
Antigen processing and presentation involve a series of events startingwith enzymatic fragmen-
tation of the source protein antigen, selection of one or more of the resulting peptides by MHC
molecules, and export of the resulting pMHCs to the APC cell membrane, where these complexes
are stably displayed awaiting T cell arrival and scrutiny (Figure 1). CD8+ cytotoxic T cells rec-
ognize peptides from the cytosol presented by MHC class I molecules, which are expressed by
all nucleated cells. In contrast, CD4+ T helper cells recognize peptides that have been sampled
from the endocytic pathway and presented by MHC class II molecules, which are expressed by
professional APCs. This dichotomy hints at the overall recognition and effector functions of the
two classes of MHC molecules: Through MHC class I, CD8+ cytotoxic T cells gain access to
information about intracellular threats in any dividing cell and may try to eradicate infected or
transformed cells; through MHC class II, CD4+ T helper cells gain access to information about
extracellular threats and may coordinate the response of other cells (3).
MHC classes I and II are heterodimeric, transmembrane glycoproteins forming a unique, ex-
tended peptide-binding groove that accommodates peptides (Figure 2). Through a few primary
anchor positions, the MHC establishes a stable and broadly specific peptide interaction. A subtle
but important difference exists between MHC classes I and II: Peptides bound to MHC class I
tend to be short (typically 9 amino acids) and confined within the peptide-binding site of MHC
class I, whereas peptides bound to MHC class II tend to be longer (typically 15 amino acids) and
extend out of the peptide-binding site of MHC class II (5).




































































































































(a) The MHC class I antigen-presenting pathway. Proteins transcribed and translated are proteolytically
processed in the cytosol by the proteasome; peptides are translocated into the ER via TAP and potentially
undergo further trimming by ERAP prior to binding to de novo synthesized MHC I molecules in the ER; a
quality control step is completed (not shown); and the resulting pMHCs are translocated to the cell surface
for CD8+ T cell scrutiny. (b) The MHC class II antigen-presenting pathway. Exogenous antigens are taken
up by APCs by endocytosis, and peptides are generated by enzymatic fragmentation and traffic to MIIC. De
novo synthesized MHC class II molecules bind to CLIP and traffic to MIIC. Here, controlled by HLA-
DM/DO, the CLIP peptide is removed and the incoming peptides are offered to MHC class II molecules.
The bound peptides are exported as pMHCs to the cell surface for CD4+ T cell scrutiny. Abbreviations:
APC, antigen-presenting cell; β2m, β2 microglobulin; CLIP, MHC class II–associated invariant chain
peptide; ER, endoplasmic reticulum; ERAP, ER aminopeptidase; Ii, invariant chain; HLA, human leukocyte
antigen; MIIC, MHC class II compartment; pMHC, peptide–MHC complex; TAP, transporter associated
with antigen processing; TCR, T cell receptor. Panel adapted with permission from Reference 4; copyright
2012 Springer Nature.
A brief historical account of the paradigm shift to the modern view of T cell recognition
is warranted. Since the early 1900s, it has been known that the outcome of allogeneic trans-
plantation is under genetic control. This eventually led to the identification of the MHC gene
complex [generically MHC, H2 in mice, and HLA (human leukocyte antigen) in humans]. The
genetic organization and polymorphisms of the HLA were established through a seminal series
of international histocompatibility workshops. The importance of HLA typing and matching


















































































































Structure of MHC class I and II molecules. An extended peptide-binding groove is formed between two
parallel alpha helices situated over a floor made up of an antiparallel beta-sheet. The binding groove for
class I is closed, whereas the binding groove for class II is open. The T cell receptor (TCR) interacts with the
peptide–MHC complex predominantly via six complementarity-determining regions (CDRs), three from
each chain. The two CDR3s interact mainly with the peptide. Figure courtesy of Kamilla Kjærgaard Munk.
became apparent, in particular for bone marrow transplantation, and the association between
HLA and autoimmune disease was established (6). Seemingly unrelated experiments conducted
in the mid-1940s hinted at antibody responses being under genetic control. Eventually, single
immune-response (Ir) genes could be identified (7),MHC was found to be in close genetic linkage
with Ir (8) [today, we know thatMHC and Ir genes are one and the same (6)], andMHCwas found
to be in control of collaborations between B and T cells, as well as between macrophages and T
cells (6). In 1974, Zinkernagel & Doherty (9) showed that virus antigens were recognized in an
MHC-restricted manner. In 1978, Benacerraf (10) and Rosenthal (11) independently proposed
that MHC specifically selected antigen fragments and presented them to T cells; however, the
nature of MHC control of immune responsiveness remained hotly contested for almost another
decade (see Reference 12 for a vivid account by Jan Klein of a period of “great, great confusion”).
All of the components that are now known to control the specific interaction between T cells
and APCs—the TCR, the MHC, and the antigen—were initially poorly defined, as was the
cellular interaction: Did it involve one or two T cell–derived receptors recognizing one or two
APC-derived ligands (antigen and MHC), either as two separate ligands, as a single complex
ligand, or as an altered ligand? These puzzles were answered, one at a time: Peptides, not intact
proteins, are the true antigenic ligands (13, 14); the MHC is the only other APC-derived ligand
needed (15); and the TCR is responsible for both peptide specificity and MHC restriction (16).
The core question of the nature of the interaction between peptides and MHC was finally
answered in a series of functional, biochemical, and structural experiments culminating around
1985–1987. In 1985, Babbitt et al. reported that appropriate peptides interacted in a specific and
saturable manner with affinity-purified MHC class II molecules in a biochemical in vitro assay
(17) and demonstrated that this correlated with the ability to stimulate T cells with peptide–MHC
class II complexes. Shortly thereafter, Buus et al. reproduced and extended these biochemical and
functional findings (18). Rather surprisingly and despite the low affinity of the interactions mea-
sured, the biochemically generated peptide–MHC class II complexes were found to be very stable.
In rapid succession, it was shown that immunogenic peptides bind strongly to their MHC restric-
tion elements, supporting the hypothesis of determinant selection (19); that different peptides
restricted to the same restriction element compete for biochemical binding to that MHC (19–21)
and compete for presentation to T cells restricted to that MHC (19); and that the peptide binding
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site is made up of both chains of the MHC class II molecule (19). The first indications of amino
acid similarities between peptides binding to the same MHC class II molecule were also provided
(19–21).Observing that less than 10% ofMHC class II molecules could bind the offered peptides,
Buus et al. suggested that affinity-purified MHCmolecules were largely preoccupied with natural
self-peptides (22), an observation that was confirmed by acid elution experiments (23).Completing
this paradigm shift, in 1987 Bjorkman et al. (24) crystallized an MHC class I molecule and iden-
tified a structure with a unique peptide-binding groove, which appeared to hold peptides in an
extended conformation. The polymorphic amino acid positions of the MHC were predominantly
found in this peptide-binding region, where they affected peptide binding and T cell recogni-
tion (25). A similar polymorphic peptide-binding structure was eventually found in MHC class II
molecules (26).
Peptide binding to MHC is the single most selective event contributing to the outcome of
antigen processing and presentation (27). It is currently determined using one of two complemen-
tary experimental approaches: one that investigates which synthetic peptides will bind to MHC
molecules in vitro, and another that investigates what the MHC has already bound in vivo. The
in vitro binding approach uses biochemical assays such as gel filtration, a robust and accurate as-
say (18) and,more recently, high-throughput, preferably homogenous, assays (for an overview, see
Reference 28) to quantitate the binding of synthetic peptides to MHC molecules that have been
purified from appropriate cell lines (28) or generated recombinantly (29). Any peptide that can be
synthesized can be examined. A variant using positional scanning combinatorial peptide libraries
affords a particularly comprehensive and unbiased analysis of MHC class I specificity (30). A large
body of this kind of data has been deposited at the Immune Epitope Database (IEDB) (31). The in
vivo binding approach uses natural peptides that have been acid-eluted off affinity-purified MHC
molecules. In 1991, seminal work by Falk et al. used Edman degradation to analyze pools of eluted
peptides (32). In 1992, similarly seminal work by Engelhard used tandem mass spectrometry to
sequence individually eluted peptides (33).
Several earlier manuscripts and reviews have described the developments within the field of
immunoinformatics and prediction of MHC antigen presentation, including References 34–36.
Annually more than 30 papers are published describing novel approaches to resolve the task of
predicting antigen presentation by MHC. In this review, we do not seek to provide a compre-
hensive overview of all the different contributions within the field, but rather provide a focused
perspective of the essential discoveries and achievements, provide guidance on best practices, and
outline limitations and remaining challenges. A summary of the tools described in this review is
included in Table 1.
PREDICTION OF PEPTIDE-MHC BINDING
Simple Motif-Based Models
The observation that MHC molecules have binding preferences that could be characterized in
terms of simple binding motifs led to the development of the first motif-based MHC binding
prediction methods. In early work by Sette et al. (45), motifs for the two mouse MHC class II
molecules, I-Ed and I-Ad, were described in terms of quantitative scores defined from position-
specific propensities. Later work refined this picture of MHC binding motifs by defining anchor
positions located with well-defined sequential spacing in the peptide where only a limited set of
tolerated amino acids substitutions were allowed (32). These works further demonstrated how the
anchor positions often were shared between differentMHCmolecules but that the binding motifs
were unique (32). Based on this, more refined motif-based prediction schemes were defined with
differential scoring of the amino acid propensity depending on the peptide position. A prominent
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Table 1 MHC binding prediction methods available and described in this review
Method URL Pan-specific Includes EL data Reference
Class I
NetMHC http://www.cbs.dtu.dk/services/NetMHC No No 37
NetMHCpan http://www.cbs.dtu.dk/services/NetMHCpan Yes Yes 38
MixMHCpred https://github.com/GfellerLab/MixMHCpred No Yes 39
MHCflurry https://github.com/openvax/mhcflurry No Yes 40
BIMAS Decommissioned on March 8, 2019 No No 41
SYFPEITHI http://www.syfpeithi.de No Yes 42
SMM http://tools.iedb.org/mhci No No 43
Class II
NetMHCIIpan http://www.cbs.dtu.dk/services/NetMHCIIpan Yes No 44
Abbreviation: EL, eluted ligand.
example is the SYFPEITHI prediction model (46) where binding propensity scores are estimated
based on statistics from MHC class I eluted-ligand data (EL data). Using direct binding assays,
Stryhn et al. employed positional scanning combinatorial peptide libraries to identify both the
MHC class I anchor positions and propensity scores of the different amino acids at each peptide
position, thus providing a full characterization of the MHC binding motif (30). Alternatively, the
scores were based on measured binding data from single-substitution analogs of known ligands
(47). Eventually, both the eluted ligand approach (48) and the single-substitution approach were
extended to MHC class II binding ligands (49).
Toward the First Machine Learning Models
While these pioneering motif-based prediction methods enabled the first cataloging and classifi-
cation of MHC binding preferences, it soon became clear that they very often suffered from low
sensitivity and hence often failed to identify large proportions of validated MHC-binding pep-
tides. Inspired by advances in machine learning, the mid- to late 1990s saw the development of
a second generation of prediction models. In this kind of approach, models were trained on ex-
perimental data, aiming to minimize the error between the predictions of the model and a set of
experimental measurements. The resulting mathematical model could then be applied to make
predictions on new data: in this case, new peptide–MHC pairs of interest.
The BIMAS model proposed by Parker et al. was the first example of a predictor trained
directly on experimental data, fitting a matrix model using linear regression (LR) on the mea-
sured half-life of HLA-A2 complexes with bound peptide (41). Later, more complex models were
proposed, including artificial neural networks (ANNs) (50–55), hidden Markov models (HMMs)
(56, 57), and QSAR (quantitative structure-affinity relationship)-based regression models
(58).
A common factor limiting the success of these models was the insufficient availability of ex-
perimental data characterizing peptide binding to the investigated MHC molecules. By way of
example, the ANN model proposed by Milik et al. (51) was trained on merely ∼200 data points.
Because machine learning models built on small datasets often contain more parameters than can
be confidently estimated from the data, the performance of the early machine learning methods
often suffered from a phenomenon generally known as overfitting. Nonetheless, some of the sim-
pler models such as BIMAS have, over the years, demonstrated a high performance in epitope
prediction.
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Larger Peptide–MHC Databases: More Reliable Prediction Methods
With the formulation of novel, high-throughput peptide–MHC-binding assays (see above) and
with the creation of large publicly available databases covering both a broader set of MHC
molecules and a more in-depth characterization of individual MHCmolecules [SYFPEITHI (46),
MHCBN (59), MHCPEP (60), and IEDB (31)], it became possible to develop and validate more
complex predictionmodels, includingmethods based onmachine learning.Early examples of such
models included LR models such as stabilized matrix method (SMM) (43, 61) and higher-order
regression (HR) models such as SVMHC (62), SVRMHC (63), and NetMHC (55). Here, the HR
models allow incorporation of correlations between neighboring residues and are hence expected
to better capture nonlinear relationships between peptide sequence and MHC binding.
With the growing list of available methods, the lack of objective benchmarks and criteria for
the evaluation of predictive performance became critical. Peters et al. (64) published one of the
first attempts to rigorously assess the state of the art in the field by comparing the performance of
a panel of previously published and publicly available methods to the performance of three meth-
ods, ARB (average relative binding), SMM, and NetMHC, that had been retrained and bench-
marked on common data. One important conclusion from this benchmark study was that SMM
and NetMHC (called ANN in the benchmark) overall outperformed all other methods included
in the analysis. Furthermore, the retrained versions of the tools outperformed the earlier versions
of the same methods, strongly suggesting that continuous retraining of prediction methods as
additional data become available is essential to maintain optimal performance. Another obser-
vation was that the SMM and NetMHC methods achieved comparable performance for larger
datasets, suggesting that the abovementioned nonlinear correlations play a minor role in defining
the peptide–MHC interaction.Peptides bind to theMHC in an extended conformation (Figure 2)
(65), and as a first approximation, the strength of the interaction should depend on the sum of the
binding energies of the individual amino acids, suggesting that peptide–MHC binding is mostly a
linear problem. This may explain why simple LR methods have achieved high predictive perfor-
mance for the peptide–MHC system, outperformingmore complex structure-basedmethods (66).
Later benchmark studies demonstrated that neural network–based methods, such as NetMHC,
can indeed improve the prediction of T cell epitopes (67). However, these neural network meth-
ods were all shallow (most often limited to a single hidden layer), further supporting the notion
that nonlinear contributions to peptide–MHC binding are limited.
In parallel with the development of accurate prediction methods for the MHC class I system,
similar efforts were dedicated to the prediction of peptide binding toMHC class II molecules.The
open binding groove of MHC class II, which allows longer peptides to protrude out of the bind-
ing cleft (68), makes peptide binding predictions of MHC class II considerably more challenging
compared toMHC class I.While peptides interact withMHC class II using a binding core of nine
residues, they are generally out of frame in terms of the location of this binding core. Therefore,
to ensure accurate model training, peptides must be aligned to a common binding core. The list
of machine learning frameworks proposed to solve this challenge is long, including HMMs (69),
SVMs (support vector machines) (70, 71), Gibbs sampling (72), and ANNs (53, 73), among others.
An important algorithmic development toward accurate modeling of pMHC II binding was the
NNAlign method (Figure 3) (73, 74). Using an iterative loop over a set of training peptide data
with measured MHC binding values, NNAlign identifies the optimal binding core of nine amino
acids and at the same time predicts binding for a given peptide given the current model parame-
ters; next, it updates the model parameters to minimize the difference between the predicted and
measured binding. Through this iterative procedure, the algorithm achieves simultaneous align-
ment and binding motif characterization.
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Predicted  motifs
Predicted  binding


















































The NNAlign machine learning framework. Different kinds of peptide–MHC binding data are integrated in a machine learning
framework leveraging information between multiple MHC molecules and peptide length, resulting in a pan-length, pan-MHC
prediction method that captures individual binding motifs and allows for accurate epitope prediction. Abbreviations: BA, binding
affinity; EL, eluted ligand.
Benchmark studies soon demonstrated that, in addition to MHC class I, ANN-based models
also achieved the highest predictive power for class II (75). Over the years, the NNAlign frame-
work (73) has been refined continuously, and it now serves as the main framework for training
NetMHC and NetMHCII (as well as NetMHCpan/NetMHCIIpan, further discussed below)
(44, 76, 77).
An important shortcoming of the early machine learning prediction methods for MHC class I
peptide binding was that they (as most other early machine learning methods) required the input
data to be of uniform length. Consequently, individual prediction methods had to be developed
for each peptide length separately. This severely limited the predictive power of these tools since
very limited binding data were available for peptides with lengths outside the canonical range of
9–10 amino acids. As a workaround, approximation methods were used to assess the binding of
peptides of a length that was different from that used to train a given prediction model. For in-
stance, Lundegaard et al. (78) proposed a simple approximation where prediction models trained
on 9-mer peptides were used to predict binding of peptides of length 8, 10, and 11. This ap-
proximation assumes that peptides of length other than 9 are accommodated through a structural
change maintaining the MHC anchor binding preferences while adapting to the closed MHC
class I binding pocket. For longer peptides, this results in a binding mode where one or more (de-
pending on the peptide length) consecutive residues bulge out of the binding cleft, whereas 8-mers
assume amore extended conformation. By representing these different bindingmodes as deletions
(in the case of bulging) and insertions (in the case of extension), one can calculate the affinity of
any peptide of length 8–11 as the average predicted affinity of all possible pseudo-9-mer binding
modes.
Whether length-specific modeling or approximation methods were used, the results were a
lower accuracy for predictions of non-9-mer peptides (37). Moreover, these approaches could
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account for neither the length distribution ofMHC-bound peptides nor the peptide length prefer-
ence variations between individual MHC alleles. For example, in the earlier versions of NetMHC,
predictions for non-9-mer peptides were extrapolated from prediction models trained on 9-mer
peptides using the approximation as described above. As a result, on average, the method pre-
dicted the same number of binders for each peptide of length 8–11. This was in clear contrast to
the length preference observed for epitopes and naturally presented HLA binders (79, 80), where
the vast majority of peptides are 9 amino acids long, leading to a large proportion of false positives
among the predicted non-9-mer binders.
Aiming to address the differential peptide length preferences of MHC class I molecules, Trolle
et al. (80) suggested an empirical length-dependent correction of the peptide prediction score.
This length correction effectively adjusted the modeled peptide length preference to that ob-
served in naturally presented HLA binders and greatly improved the identification of T cell epi-
topes. Concurrently, advances in the NNAlign framework allowed it to train prediction methods
based on datasets of different peptide lengths (37). In this case, however, the reconciliation of
peptides of any length onto the 9-mer binding mode was performed during training, allowing
peptides of all lengths to be included in the construction of the model and effectively enabling
the development of a pan-length prediction method. In addition, the method allowed for bind-
ing modes with C- or N-terminal extensions—a phenomenon suggested to occur with a small,
but non-negligible, frequency for a list of HLA-A and HLA-B molecules (examples reported in
References 81–83).This extension to theNNAlign framework afforded two important advantages.
Firstly, training single models on datasets covering different peptide lengths allowed the method
to leverage information obtained from datasets representing peptides of different length. Sec-
ondly, but perhaps more importantly, the pan-length approach allowed the peptide length profile
to be learned for different MHC molecules. Later, an alternative approach for pan-length model
development was proposed by O’Donnell et al. (40). In their MHCflurry model, peptides of vari-
able length were transformed using a fixed-length 15-mer peptide and an encoding designed to
preserve the location of MHC anchor positions. Several benchmark studies have demonstrated
comparable performance between these two approaches (84–87).
Selecting a Threshold to Define Binders
Another critical issue faced when applying (predicted or measured) MHC binding as a filter for
rational epitope discovery is the definition of the binding classification threshold to be used to
identify immunogenic T cell epitopes. Early work by Sette et al. (88) suggested that a measured
binding threshold of 500 nM captured most of the immunogenic CD8+ T cell epitopes for HLA-
A∗02:01. Likewise, Southwood et al. (89) analyzed the relationship between measured binding
affinity and T cell immunogenicity for a panel of HLA-DR molecules and found that a measured
binding threshold of 1,000 nM captured most of the immunogenic CD4+ T cell epitopes. How-
ever, it became clear that such a universal binding threshold was suboptimal for epitope discovery,
as several studies could demonstrate that different HLA molecules shared peptide binding reper-
toires of varying sizes (90, 91) and presented peptides in complex with MHC molecules at very
different affinity values (92). This effect was demonstrated when assessing MHC binding using
both experimental binding assays and prediction models (90, 92). To reconcile different affinity
thresholds between different HLA molecules, we have suggested that, for immunogenicity clas-
sification purposes, percentile rank scores rather than binding affinity values should be used as
thresholds (93). In short, percentile rank scores are calculated as the percentage of peptides (in a
precalculated score distribution derived from a large set of random natural peptides) that have a
better score than the peptide in question. For example, a percentile rank score of 0.1% indicates
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that only one out of a thousand random peptides is expected to obtain a prediction score better
than the query peptide. In practice, rank scores act as a normalization of binding affinity scores
over the underlying score distribution of the individual MHC molecule and are therefore useful
when equating and comparing different MHCs. Subsequent work has demonstrated how the use
of such rank scores, rather than predicted binding affinity values, led to an overall higher predictive
power when analyzing the peptidome repertoires in the context of multiple HLA molecules (94).
In this context, Paul et al. (92) went further and demonstrated, for a limited set of HLAmolecules,
that using an experimentally defined allotype-specific binding threshold was optimal. The debate
on this issue is still open, but the consensus of the field is leaning toward using percentile rank
score for epitope classification.
Dealing with HLA Polymorphism
All the prediction methods discussed up to this point have been allotype specific, meaning that
a separate prediction model needs to be developed for each individual MHC molecule. Since
11,405 HLA I allotypes are described in the current version 3.37 of the IMGT (International
Immunogenetics Project)/HLA database (95), it would be a very large undertaking to generate
binding data characterizing each of them. The extreme polymorphism of the MHC is a major
constraint in the development of allotype-specific prediction methods covering all human MHC
molecules, a goal that otherwise would be of great interest for rational epitope discovery and
personalized vaccine/immunotherapy design.
A first approach to solve this problem was based on the realizations that MHC molecules can
be clustered into groups (so-called HLA supertypes) of molecules that bind largely overlapping
peptide repertoires (96, 97) and that population-wide epitope discovery hence could be achieved
by predicting binding to individual MHC molecules representing each supertype.While this ap-
proach was somewhat successful, it also became clear that the supertype concept was an oversim-
plification. Although MHCs within a given supertype share overlapping peptide repertoires, the
overlap is far from perfect, and the success of epitope discovery could be greatly improved by using
prediction methods matching the exact MHC allotype of the population/patient of interest rather
than a supertype representative (93). A crucial advance toward achieving full and accurate cover-
age of the MHC space was the development of NetMHCpan, the first pan-specific method for
MHC class I (98). NetMHCpan was inspired by the work of Brusic et al. (99), who complemented
the peptide binding information used to train the prediction model with information about the
amino acids defining the MHC binding cleft. This made it possible to leverage information be-
tween MHC molecules and, for the first time, to generate accurate predictions for allotypes with
limited or even no binding data. Other pan-specific approaches have subsequently been proposed,
such as ADT (adaptive double threading; 100), KISS (kernel-based inter-allele peptide binding
prediction system; 101), and PickPocket (102), each implementing different representations of
the MHC binding environment to allow for the development of pan-specific prediction models.
For class II, the first pan-like prediction model was TEPITOPE (103), which enabled peptide
binding prediction for a library of 51 HLA-DR molecules. TEPITOPE achieved this by using
virtual matrices based on similarity between binding pocket residues from a small database of ex-
perimentally determined binding pocket profiles. Other prediction models for class II, based on
approaches similar to that of NetMHCpan described above, include MultiRTA (104), MHCII-
Multi (105), and NetMHCIIpan (44, 76, 77, 106), the last of which covers all class II proteins of
known sequence, thus enabling true pan-specificity. Independent benchmarking has subsequently
demonstrated the superior performance of the NetMHCpan/NetMHCIIpan methods for predic-
tion of peptide binding, MHC ligands, and T cell epitopes (107–109).
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The Role of MHC Binding Stability
The methods described so far have primarily been constructed to predict the peptide binding
affinity of the MHC.However,MHCmolecules must not only bind the peptides generated inside
the cell but also retain them at the cell surface long enough to be available to rare circulating
T cells of the appropriate specificity. It has been argued that the stability of the peptide–MHC
interaction, rather than binding affinity, is a more relevant property to predict T cell immuno-
genicity (110, 111). The main reason why pMHC I stability has not been used more extensively
is related to the cumbersome or low-throughput nature of current biochemical methods used
to measure the dissociation of pMHC I complexes (111). In 2011, Harndahl et al. proposed an
assay to resolve this experimental bottleneck (112). Inspired by the earlier work of Parker et al.
(41), they radiolabeled β2 microglobulin (β2m) rather than the peptide and used β2m dissociation
as measured by a scintillation proximity assay to accurately monitor peptide dissociation. Using
this assay, they could demonstrate that peptide–MHC stability rather than peptide affinity is a
better predictor of CTL immunogenicity (111). These data were later used to construct predic-
tors of peptide–MHC binding stability, and benchmarking of these predictors further suggested
that binding stability plays an important role in defining peptide immunogenicity (113, 114). At
present, datasets of peptide-MHC stability remain limited in terms of amount of data, peptide
diversity, and MHC alleles covered. This, combined with a shifting focus toward mass spectrom-
etry (MS) for sequencing immunopeptidomes (see below), has halted further the development
and a wider application of prediction methods based on peptide–MHC stability in T cell epitope
discovery.
Methods Predicting MHC Antigen Presentation
Peptide binding toMHC is arguably the single most selective event in antigen processing and pre-
sentation. Nonetheless, other events can affect the availability of peptides for T cell recognition.
Prediction methods have been developed for proteasomal cleavage (115, 116) and TAP (trans-
porter associated with antigen processing) efficiency (117, 118). Two important observations can
be made from these studies. Firstly, the steps involved in antigen processing have specificities
that can be learned and applied to identify MHC ligands. Secondly, the events of proteasomal
cleavage and TAP transport are much less specific compared to that of MHC binding. Different
methods integrating the prediction of the various steps in antigen processing and presentation
have been proposed, including NetCTL (119), NetCTLpan (93), and MHC-pathway (120) (re-
viewed in Reference 107). However, only minor improvements in predictive power have been
obtained (93). A comparison of the specificity of the proteasome, TAP, and MHC suggested that
the MHC molecules appear to have (co)evolved to accept binding of peptides generated by the
proteasome and translocated by the TAP molecules (115). Taken together, these results suggested
that, rather than serving as a specificity filter, the major concerted role for the proteasome and
TAP in the context of MHC class I antigen presentation is to deliver peptides of the appropriate
length for MHC binding. That is, the proteasome predominantly generates short peptide frag-
ments with an average length of 7–8 amino acids (121, 122), TAP preferably translocates peptides
of length 11 (118), and the combination of these two length preferences as first approximation
results in a length distribution centered around 9–10 amino acids—in agreement with the ob-
served peptide length distribution of presented MHC ligands (79, 80). Note that the specificity
of other proteases such as ERAP1 and ERAP2 can also influence the repertoire of ligands avail-
able for MHC binding (123, 124), but they have not been included in any of these prediction
approaches.
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Mass Spectrometry Characterization of MHC Ligandomes and Prediction
Methods Trained on Mass Spectrometry Ligandome Data
The peptide repertoire presented by MHCmolecules on the cell surface is commonly referred to
as the MHC ligandome or immunopeptidome. In the past decade, technological advances in pro-
teomics and MS have enabled the study of such MHC ligandomes (EL data) at an unprecedented
scale and level of detail and have established a new way of studying peptide–MHC presentation
(reviewed in Reference 125). As cells normally express multiple types of MHC molecules, a key
challenge for the interpretation of immunopeptidome data is to identify the differentMHC speci-
ficities and assign/annotate the individual peptides to one or more of these specificities. Several
experimental approaches have been proposed to solve this task, including the use of monoallelic
cell lines (126) and cell lines expressing a secreted form of specific MHC molecules (127). How-
ever, these approaches might not always be feasible, and it would obviously be more desirable to
analyze and interpret EL data obtained from cell lines, and eventually patient samples, that ex-
press several MHC allotypes. In this context, a pioneering method, GibbsCluster, was proposed
by Andreatta et al. (128). As input, GibbsCluster takes a list of peptide sequences (potentially of
variable length) and uses a heuristic search to group them into clusters by optimizing the pep-
tide similarity within clusters and the dissimilarity between clusters. Besides the sequence motif
defining each cluster, additional properties such as the ligand length distribution of each cluster
can be analyzed. Bassani-Sternberg et al. (129) demonstrated how this method could effectively
be used to deconvolute and characterize MHC class I ligand data. Later, Bassani-Sternberg &
Gfeller (39) proposed a similar method, MixMHCp, with comparable performance and predic-
tive power. Unfortunately, and irrespective of which method is applied, it is not always possible to
deconvolute the complete number of MHC specificities expressed in a given cell line, especially if
some of the different MHCmolecules have overlapping binding motifs or have highly varying ex-
pression levels. Moreover, assigning specific MHC molecules to the different clustered solutions
relies on manual annotation and prior knowledge of allotype-specific MHC binding (130, 131).
Gfeller et al. suggested an elegant, unsupervised solution to this problem by deconvoluting and
automatically annotating HLA I motifs based on co-occurrence of alleles across large MHC lig-
and datasets (132), thereby allowing the MHC ligands to be associated with their putative MHC
restriction elements.
Whichever of the above experimental or computational solutions is adopted, the outcome is an
EL dataset with putatively annotated MHC restriction. Such data are a rich source of information
for learning the rules of MHC-mediated antigen processing and presentation and for identifying
potential T cell epitopes for both class I and class II. The amount of EL data available in the
public domain is large (and rapidly growing); however, a very large body of complementary infor-
mation exists in the form of conventional peptide binding data. By way of example, as of August 8,
2019, IEDB contains close to 1,200,000MHC ligand data points.Of these,more than 300,000 are
derived fromMHC binding assays, and the remaining are fromMHC ligand elution assays. Inves-
tigating the subset of these data characterized by single, high-resolution-typed MHC restriction,
and limiting the binding affinity data to quantitative assays, the two datasets individually cover
around 140 distinct MHC molecules. However, only 80 of these are shared between the binding
affinity (BA) and EL data types. Given this complementarity, it is attractive to develop prediction
algorithms that can benefit from both data types. One such approach was proposed by Jurtz et al.
(38), who used a novel neural network architecture that integrated BA and EL data into a single
training scheme, allowing information to be leveraged across the two data types. This resulted
in a machine learning method that could learn (and predict) both the binding affinity of a given
peptide and its likelihood of being an MHC ligand. This modeling framework, which resulted
in the NetMHCpan-4.0 method, was shown to achieve predictive performance beyond that of
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models trained on each data type (BA or EL) separately for both for class I and class II (38, 133).
An alternative approach of integrating BA and EL data was later implemented by the MHCflurry
tool (40), where the difference between qualitative EL and quantitative BA data was handled in
the data presentation to the machine learning method. The results of this approach further sup-
ported that combining BA and EL data generated superior prediction models and in particular
demonstrated improved performance for prediction of EL data.
As stated above, a key challenge and limiting factor for the interpretation and use of EL data is
the deconvolution step required to assign each ligand to its putative MHC restriction element(s).
Recently, we have proposed a framework that allows complete MHC peptidome deconvolution
of EL data and, simultaneously, its automatic annotation to individual MHC molecules (85). The
framework is inspired by the work of Gfeller et al. (132) and is an extension of the NNAlign
neural network framework described above. The method, termed NNAlign_MA, is capable of
taking single-allele datasets (peptides assigned to single MHCs) and multiallele datasets (pep-
tides with multiple options for MHC assignments) as input and fully deconvoluting the individ-
ual MHC restriction of all peptides while simultaneously training a pan-specific MHC binding
predictor. Benchmark studies of the method have demonstrated an improved performance of this
framework compared to other state-of-the-art methods for prediction of MHC eluted ligands and
T cell epitopes for both MHC class I and II. Importantly, this method could effectively expand
the knowledge base of MHC molecules with characterized binding motifs (85).
EL data inherently contain information about the antigen processing precedingMHC presen-
tation. For MHC class II, analyses of large-scale EL datasets have revealed the presence of clear
C- and N-terminal motifs consistent with specific proteolytic cleavage signals (131, 133), and in-
corporation of these cleavage signals has been demonstrated to boost prediction of MHC class II
ligands (133).
Exceptions to the Canonical Rules of MHC Antigen Presentation
The availability of large and diverse ligand datasets covering a broad range of different MHC
molecules from a diverse list of species, including humans, nonhuman primates, mice, cattle, and
swine, has allowed the field to investigate in great detail the rules that define antigen presenta-
tion, especially for MHC class I. The striking conclusion from these analyses is that the rules are
surprisingly simple and largely consistent across mammalian species. In the vast majority of cases,
the selection for antigen presentation is predominantly governed by theMHC [in nonmammalian
species like chicken, this selection is also affected by polymorphic genes such as TAP and tapasin
(TAPBP) controlling antigen processing and peptide loading (for a review, see Reference 134)], and
the rules for binding to MHC across species are defined by MHC-specific binding motifs char-
acterized by anchor positions with a well-defined spatial separation shared among the majority of
MHCs (P2 and P for class I, and P1, P4, P6, and P9 for class II).Historically, there has been some
controversy about whether all presented peptides adhere to these rules. However, recent analyses
of extensive MHC ligand datasets, and reanalysis of historic epitope data, have confirmed that the
vast majority of the outliers contain nested peptides that do adhere to the rules (82, 135). This
being said, analyses have also revealed a minor MHC ligand population that follows noncanonical
modes of MHC antigen presentation. These noncanonical modes include presentation of ligands
extending beyond the C terminus (and to a lesser degree N terminus) of the class I binding cleft
(81–83), ligands with 8- or 10-mer cores for binding to MHC class II (136), and nongenomically
templated peptides generated by proteasomal splicing of protein fragments (137, 138).While the
true nature of these exceptions to the conventional rules of MHC antigen presentation has been
indicated in several studies, the vast majority of currently characterized T cell epitopes adhere
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to the canonical rules. In terms of MHC presentation, it is important to underline that current
peptide–MHC binding prediction models such as NetMHC, NetMHCpan, and NetMHCIIpan
all provide the possibility of incorporating and learning from peptides with noncanonical binding
modes as more data supporting their biological relevance become available.
BENCHMARKING
As in most of computational biology, evaluating different MHC binding prediction algorithms
relies on the availability of metrics and datasets that allow researchers to benchmark and compare
their performances (139). Such benchmarks are valuable for both users, who are getting guidance
on what algorithm to apply, and developers, who can objectively demonstrate if they have found a
superior approach. Ideally, such benchmarks should be conducted on new data, meaning that the
benchmark data were not used in the development and training of the evaluated algorithms. As-
sembling large enough experimental datasets for this purpose can be costly and time consuming,
and keeping such data from public view just for benchmarking purposes is not justifiable. Auto-
mated benchmarks for MHC class I andMHC class II binding predictions have been added to the
IEDB website to circumvent this problem; these benchmarks run all data that are newly included
in the weekly database releases through a set of prediction tools and compare the predicted and
measured binding assessments (108, 109). Any tool developer can register to include their tool in
these benchmarks.While each of these microbenchmarks tends to have few data points, aggregat-
ing their results over time should reflect the overall reliability of different algorithms. One issue
that has arisen with this automated approach is that new experimental datasets that characterize
peptide–MHC binding in an appropriate way for inclusion in these benchmarks are published
much less frequently than one would hope for. Many datasets only include positive data points or
do not report any quantitative measurements at all. Furthermore, as not all prediction methods
can make predictions for all MHC alleles or all peptide lengths, comparisons between different
methods are nontrivial. While this makes the results of these automated benchmarks less defini-
tive than one would hope for, the general principle of automating the evaluation of prediction
algorithms on newly available data is an important addition to the traditional approach of having
tool developers demonstrate their algorithm performance as part of their tool publication.
T CELL EPITOPE DISCOVERY
While prediction of peptide–MHC binding is an interesting problem in itself, the ultimate goal of
most real-life applications is the prediction and identification of T cell epitopes.Most pipelines for
T cell epitope discovery include prediction of either MHC binding or likelihood of MHC antigen
presentation (representative examples include References 140–143). Given this, it is important to
assess the performance of different prediction methods in terms of predicting T cell epitopes
and to define the optimal modus operandi for each method. While substantial efforts have been
dedicated to assessing the power of current tools’ ability to predict MHC–peptide binding (see
above), limited work has been published evaluating available methods for their predictive power
relative toT cell epitope discovery.However, the current consensus in the field is that the following
methods are leading: MixMHCpred (39), MHCflurry (40), and NetMHCpan-4.0 (38) for MHC
class I, andNetMHCIIpan (44) forMHC class II. For class I, these methods have been applied and
benchmarked in a series of recent publications (36, 84–87), each demonstrating a very high and
comparable performance for T cell epitope identification. As discussed above, the recommended
use of these methods is to select predicted epitopes by use of a percentile rank threshold.The value
of this threshold depends on the scope of the given application. If the goal is to find some epitopes
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(not necessarily all) and avoid spending excessive resources on false positives, a stringent threshold
of 0.25% or 0.5% rank should be used. Benchmark studies including References 38, 86, and 144
have demonstrated that this threshold will identify ∼70% of the epitopes while discarding up to
99.5% of nonimmunogenic peptides. In contrast, if one is interested in identifying all epitopes—or
in avoiding any false negatives (i.e., for avoidance of immunogenic biosimilars)—a less stringent
threshold of 2% rank should be selected. Using such a threshold will ensure that the vast majority
of epitopes are identified (∼95%), albeit at the expense of a loss in specificity (38, 86).
In the context of immunogenicity, where there is a need to identify a few epitopes out of many
thousands of peptide candidates, even a specificity of 99% translates into a relatively high propor-
tion of false-positive predictions, and the false-discovery rate (FDR) in epitope discovery projects
rarely falls below 50%.This has contributed to the notion that epitope prediction remains a daunt-
ing problem (145). However, these FDRs should be appreciated in light of the fact that peptide
immunogenicity is in general a rare event. Less than 0.05% of randomly selected peptides within
a given pathogen are immunogenic (27); this would result in an FDR of 99.95% if peptides were
selected at random. Seen in this light, an FDR of, for instance, 75% is a large improvement.
However, from an applied perspective, this might still be prohibitive. Several issues are at play
in explaining the high proportion of false predictions. Yewdell & Bennink (27) suggested that the
TCR repertoire only matched 50% of the presented pMHCs; thus, even a perfect predictor of
presented pMHCs would, in terms of immunogenicity, never achieve an FDR lower than 50%.
When focusing on single proteins with known epitopes, current peptide–MHC binding predic-
tion tools identify the majority of ligands and epitopes within the top 0.5% of the peptides of
the source proteins (38, 86). However, studies suggest that not all proteins are available for MHC
antigen presentation; if not accounted for, this could in itself lead to a high FDR (131). It is not
fully understood what dictates this differentiation between the proteins that provide peptides for
antigen presentation and those that do not, but besides protein expression and abundance (146,
147), properties related to protein degradation and translation efficiency are likely involved (131).
MS has been suggested as an approach to limit the FDR, either as a means to identify proteins
available for MHC antigen presentation or as a strategy for antigen discovery (148, 149). While
such approaches are powerful, it is critical to realize that the gain in specificity provided by MS
comes at a very high price in terms of loss of sensitivity. Even with the most recent technological
(150) and computational (151, 152) advances,MS studies of peptides eluted off MHC only capture
a small proportion of the set of peptides presented by MHC, and most often fail to identify a sub-
stantial proportion of validated epitopes (148, 149, 153). Given this, we believe that any rational,
real-time T cell epitope discovery will remain dependent on in silico prediction methods (148).
Studies have suggested that properties of the peptide side chains facing out from the MHC
binding groove can favor interaction with the TCR, and such properties have been implemented
into T cell epitope prediction models with some success (154, 155). Likewise, studies have investi-
gated how the similarity betweenMHC-presented peptides and the self-peptidome (144, 156) and
microbiome can impact the likelihood of a relevant TCR being present in the T cell repertoire of
a given individual due to positive and negative T cell selection (157). The common conclusion of
these studies is that,while some deselection of peptides with high self-similarity could be observed,
the predictive power of the proposed similarity models has been modest at best. This suggests that
we still have a very inadequate picture of the rules of TCR cross-reactivity that define functional
similarities between peptides.
Another critical issue faced when doing rational epitope discovery is the inherent diversity of
the pathogens and the resulting host immune responses; rarely will different members of a pop-
ulation share the same HLA allotypes and be infected with the same pathogen strains. Different
approaches have been suggested to deal with this problem, including focusing on binding to sets
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of prevalent and functionally different HLA alleles [using for instance the HLA supertypes (96,
97)] and selecting peptides from genomic regions conserved across pathogenic strains (158).Other
approaches such as Mosaic, OptiTope, Episelect, and PopCover (reviewed and benchmarked in
Reference 159) have explicitly dealt with the pathogen or HLA diversity by selecting peptides that
in concert provide a broad HLA and pathogen strain coverage.
DISCUSSION AND CURRENT CHALLENGES
In 1999, we proposed a Human MHC Project describing and predicting peptide binding for all
human MHC molecules (160). Covering even the 413 classical HLA class I molecules registered
in the contemporary version 1.1 of the IMGT-HLA database was a challenging and distant goal.
The past decades have seen significant improvements in how peptide–MHC binding data are
addressed experimentally. However, the number of registered molecules has increased to 11,405
(version 3.37, July 2019) and is still growing, and the development of pan-specific predictors is the
only reason why the peptide binding characteristics can be said to have been solved for all human
MHC molecules, now and in the future.
In this review,we have outlined the development of these highly successful predictionmethods.
Not only do they cover all current and futureMHCmolecules, but they have also achieved levels of
accuracy that are second to none compared to computational predictors in other areas of biology.
Nonetheless, there is still a lot to do: Current predictors have important limitations, including
significant aspects of antigen presentation or recognition that are covered poorly, or not at all.
There are undoubtedly important new biological discoveries waiting to be made and included in
future predictors. Some examples are given below.
The predictive power of a machine learning tool is only a good as the data used for training.
Posttranslational modifications (PTMs) such as phosphorylation, glycosylation, deamidation, etc.
are known to influence the specificity of MHC binding and presentation (161–163); however,
very limited data and no reliable prediction methods incorporating PTMs are currently avail-
able. Similarly, there is a known underrepresentation of the amino acids cysteine in MHC ligand
datasets (132), leading to low predictive power for cysteine-containing peptides. Different correc-
tive measures have been suggested to correct for this, including replacing cysteine with an X when
representing a peptide sequence in NetMHC predictions (144).
All models described in this review are very simple in terms of the underlying machine learning
framework: All are either simple linear-matrix-based (MixMHCpred) or feedforward neural net-
work (the NetMHC suite and MHCflurry) models. Over the last few years, the field of machine
learning has been revolutionized by the development and application of so-called deep neural
network methods combining different network functions such as CNN (convolutional neural net-
work) layers, LSTM (long short-term memory) layers, and FFNN (feedforward neural network)
layers into deep (i.e., containing multiple layers) and complex network architectures. While such
deep methods have proven useful within bioinformatics and biology in general (164, 165), their
impact on the prediction of peptide–MHC binding has been limited (36, 86, 166). The meager
benefit may be attributed to the binding of short peptides in an extended conformation, as de-
scribed earlier, which largely can be approximated as a linear system, as attested by the satisfactory
performance of shallow neural networks and even matrix-based prediction methods. However,
future work and further independent benchmarking are needed to fully evaluate the potential of
deep methods in the context of predicting MHC antigen presentation and T cell epitopes.
Several aspects of the underlying biology underlying MHC antigen presentation are poorly
understood and described. One example is the abundance of protein antigens available for pro-
cessing and presentation (146, 147). Studies ofMHCEL datasets have suggested that high protein
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expression [as measured by RNA sequencing (RNA-seq) expression] can compensate and allow
for antigen presentation of relatively weak MHC-binding peptides (126, 167). However, how to
optimally integrate the information contained within RNA-seq data is not trivial, and no publicly
available prediction method currently offers the integration of expression data. Another example
is the recent discovery of the TAPBPR quality control mechanism, which is believed to ensure
that only peptides stably bound to MHC class I are exported to the APC surface and presented
(168).
T cell recognition requires that pMHCs are matched by an appropriate TCR in the repertoire
of the individual in question. This repertoire is uniquely shaped in a self-referential manner
through thymic events that are controlled by MHC and by the specificity and cross-reactivity
of the TCR, the latter of which we know very little. Finely characterizing the rules of T cell
recognition may be the single most important new development to be done. Ideally, one
should aim to generate recombinant (preferably soluble) TCRs, establish efficient trimolecular
TCR:peptide:MHCbinding assays, generate large columns of such interaction data, and construct
the corresponding predictors. If this could be done, then the entire T cell repertoire of an indi-
vidual could be modeled. This goal is already being pursued. Analyses of TCR data suggest that
TCRs sharing common cognate peptide–MHC ligands share tractable common sequences (169,
170) and structural properties (171), in principle allowing for the prediction of T cell ligands (172,
173). Currently, the performance of such prediction models is severely hampered by the limited
amount of data available. The majority of the data are, at present, limited to the CDR3 segment
of the TCR beta chain. Lanzarotti et al. (171) have demonstrated that this gives an inadequate
view of TCR specificity, suggesting that paired TCR alpha and beta sequence information will be
needed. Recent technological advances have greatly improved researchers’ ability to obtain such
paired sequence information from epitope-specific T cells (174). As more of this kind of data be-
come available, it is very likely that reliable TCR:peptide:MHC binding predictions will become a
reality.
Another T cell phenomenon, immunodominance, is also poorly understood.This is a situation
where the immune response in a given patient is predominantly focused toward a limited subset
of the available T cell epitopes, causing a hierarchy of immune responses in terms of magnitude
and prevalence. It is not clear what defines this hierarchy. Differential features of HLA antigen
processing and presentation, and properties of the T cell repertoire shaped by infection history,
precursor frequencies, and the VDJ (variable–diversity–joining) germ lines of the individual, are
likely to play a critical role (175, 176).
Addressing these unsolved questions will require continued basic research on antigen pro-
cessing and presentation, as well as on T cell recognition and responses. This will go hand in
hand with technological developments supporting large-scale and high-throughput assays of the
same.
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